Rhythm Pharmaceuticals (RYTM): Precision Obesity Pivot Grabs Headlines

While Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) faces precocious currency burn, hedge funds are piling into the banal owed to its palmy precision obesity pivot, which separates it from the broad-market GLP-1 (Ozempic/Wegovy) hype. In caller months, the steadfast has registered a bid of landmark regulatory wins for their pb drug, IMCIVREE. In mid-March, the FDA granted afloat support for IMCIVREE to dainty acquired hypothalamic obesity, a high-unmet-need market. In precocious March, an EU assemblage issued a affirmative sentiment for the aforesaid indication. Funds presumption this arsenic a transformative statement expansion. Unlike generic obesity, hypothalamic obesity is uncommon and often follows encephalon tumors oregon surgery. This gives Rhythm a 100% marketplace monopoly successful this niche, providing pricing powerfulness that broad-market drugs cannot match.

There is besides renewed absorption connected the rapidly scaling top-line show of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM). For the afloat twelvemonth 2025, the steadfast reported a 50% year-over-year gross increase, reaching astir $194.8 million. Investors are positioning themselves successful the banal up of the objective displacement from regular injections to oral pills. In aboriginal 2026, Rhythm initiated its Phase 3 trials for bivamelagon, a once-daily oral MC4R agonist. Smart wealth managers recognize that an oral mentation would drastically summation diligent adherence and marketplace penetration.

While we admit the imaginable of RYTM arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: Israel Englander Stock Portfolio: Top 10 Stock Picks and Billionaire Stan Druckenmiller’s 10 Small and Mid-Cap Stock Picks with Huge Upside Potential.

Disclosure: None. Follow Insider Monkey connected Google News.